NCT04124055 is a NA clinical trial of Therapeutic drug monitoring (TDM) in MDR-TB, sponsored by Jan-Willem C Alffenaar.

Who is sponsoring NCT04124055?

NCT04124055 is sponsored by Jan-Willem C Alffenaar.

What drugs are being tested in NCT04124055?

Interventions in NCT04124055: Therapeutic drug monitoring (TDM).

Is NCT04124055 still recruiting?

NCT04124055 is currently completed. Last updated 30 October 2020.

Last reviewed 2020-10-30 · How we verify

NCT04124055

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Saliva and Dried Blood Spot Therapeutic Drug Monitoring for MDR-TB in Tanzania

Completed NA Last updated 30 October 2020

What this trial tests

NA trial testing Therapeutic drug monitoring (TDM) in MDR-TB in 51 participants. Completed in 31 December 2019.

Timeline

24 September 2019

Primary endpoint
15 December 2019

31 December 2019

Quick facts

Lead sponsor	Jan-Willem C Alffenaar
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	51
Start date	24 September 2019
Primary completion	15 December 2019
Estimated completion	31 December 2019
Sites	1 location across Tanzania

Drugs / interventions tested

Therapeutic drug monitoring (TDM)

Conditions studied

MDR-TB — all drugs for MDR-TB →

Sponsor

Jan-Willem C Alffenaar — full company profile →

Who can join

18 and older, any sex, with MDR-TB. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Dried blood spot and saliva samples are collected during multidrug resistant tuberculosis (MDR-TB) treatment to measure the drug concentration of levofloxacin. Feasibility of both analytical procedures in a high burdened setting is explored.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Levofloxacin pharmacokinetics in saliva as measured by a mobile microvolume UV spectrophotometer among people treated for rifampicin-resistant TB in Tanzania.
Mohamed S, Mvungi HC, Sariko M, Rao P, et al · · 2021 · cited 17× · PMID 33675664 · DOI 10.1093/jac/dkab057
Therapeutic drug monitoring (TDM) as intervention: A cross-sectional analysis of characteristics of 173 registered clinical trials.
Zhao S, Zaytseva O, Chang X, Zhang B. · · 2022 · cited 4× · PMID 36276264 · DOI 10.1016/j.conctc.2022.101014

Verify or expand the search:

Other trials of Therapeutic drug monitoring (TDM)

Trials testing the same drug.

NCT05460390 — Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis · NA · terminated

Other recruiting trials for MDR-TB

Currently open trials in the same condition.

NCT05493267 — A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04124055 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jan-Willem C Alffenaar
Last refreshed: 30 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04124055.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing